Register Login
Register to leave comments
  • News bot June 22, 2026, 8:43 p.m.

    📋 PRAXIS PRECISION MEDICINES, INC. (PRAX) - Clinical Trial Update

    Filing Date: 2026-06-22

    Accepted: 2026-06-22 16:43:01

    Event Type: Clinical Trial Update

    Event Details:

    PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Clinical Trial Update PRAXIS PRECISION MEDICINES, INC. (PRAX) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (PRAXIS PRECISION MEDICINES, INC.):

    Product Type Development Stage Therapeutic Area Source
    0.5mg elsunersen Other Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    1mg elsunersen Other Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    sham procedure Procedure Phase PHASE3 Epileptic Encephalopathy ClinicalTrials.gov
    Placebo Other Phase PHASE3 Developmental and Epileptic Encephalopathy 1 ClinicalTrials.gov
    1.5mg/kg/day PRAX-562 Other Phase PHASE3 Developmental and Epileptic Encephalopathy 1 ClinicalTrials.gov
    1.0mg/kg/day PRAX-562 Other Phase PHASE3 Developmental and Epileptic Encephalopathy 1 ClinicalTrials.gov
    Flexibly dosed 20 mg to 100 mg PRAX-944 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    60 mg PRAX-944 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    100 mg PRAX-944 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    PRAX-114 Other Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    60 mg PRAX-114 Other Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    40 mg PRAX-114 Other Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    20 mg PRAX-114 Other Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    10 mg PRAX-114 Other Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    10 mg PRAX-114 or 20 mg PRAX-114 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    10 mg PRAX-114, 20 mg PRAX-114, and Placebo Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    60 mg PRAX-114 or 40 mg PRAX-114 Other Phase PHASE2 Post-traumatic Stress Disorder ClinicalTrials.gov
    Part B: 120 mg PRAX-944 and Placebo Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    Part B: 120 mg PRAX-944 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    Part A: 20 and 40 mg PRAX-944 Other Phase PHASE2 Essential Tremor ClinicalTrials.gov
    PRAX-628 Other Phase PHASE1 Healthy ClinicalTrials.gov
    30mg PRAX-628 Other Phase PHASE2 Focal Onset Seizure ClinicalTrials.gov
    20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks Other Phase PHASE2 Focal Seizure ClinicalTrials.gov
    PRAX-222 - Fixed Doses Other Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Optional Ascending Doses Other Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Initial Ascending Doses Other Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    PRAX-222 - Initial Dose Other Phase PHASE1 SCN2A-DEE ClinicalTrials.gov
    60 mg ulixacaltamide Other Phase PHASE3 Essential Tremor ClinicalTrials.gov
    vormatrogine Other Phase PHASE3 Epilepsy, Tonic-Clonic ClinicalTrials.gov
    PRAX-562 Other Phase PHASE2 SCN2A Encephalopathy ClinicalTrials.gov
    20 mg/day vormatrogine for 12 weeks Other Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    30 mg/day vormatrogine for 12 weeks Other Phase PHASE3 Focal Epilepsy ClinicalTrials.gov
    40 mg/day vormatrogine for 12 weeks Other Phase PHASE3 Focal Epilepsy ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: PRAXIS PRECISION MEDICINES, INC.
    • Ticker Symbol: PRAX

Search

News categories